Ipilimumab (anti-CTLA4), pembrolizumab and nivolumab (PD1 inhibitors) are the available ICIs used in melanoma for ipilimumab since 2014, for pembrolizumab and nivolumab since 2015. The gene discussed is CTLA4; the disease is melanoma.